Insight Molecular Diagnostics (IMDX) Receivables (2020 - 2026)

Insight Molecular Diagnostics has reported Receivables for 7 years, with the latest figure at $157000.0 in Q1 2026.

• Quarterly Receivables fell 95.56% year-over-year to $157000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $157000.0 (down 95.56% YoY) and the FY2025 annual result came in at $1.1 million, down 29.5% from the prior year.
• Receivables eased to $157000.0 in Q1 2026 per IMDX's latest filing, from $1.1 million in the prior quarter.
• Over five years, Receivables peaked at $3.5 million in Q1 2025 and troughed at $85000.0 in Q2 2024.
• A 5-year average of $1.1 million and a median of $593000.0 in 2023 frame the typical range for Receivables.
• The sharpest annual moves came in 2025 and 2026: Receivables surged 2098.76% in 2025, then slumped 95.56% in 2026.
• Over 5 years, Receivables stood at $1.4 million in 2022, then sank by 65.07% to $489000.0 in 2023, then jumped by 227.2% to $1.6 million in 2024, then fell by 29.5% to $1.1 million in 2025, then sank by 86.08% to $157000.0 in 2026.
• According to Business Quant data, Receivables over the past three periods registered $157000.0, $1.1 million, and $258000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.